DJIA 18,087.65 49.68 0.28%
NASDAQ 5,064.54 4.29 0.08%
S&P 500 2,112.36 3.44 0.16%
market minute promo


company name or ticker
Company Photos
(Click to zoom)

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q2 2014 Results - Earnings Call Transcript

2 Biotechs Race To Treat Movement Disorders

Neurocrine In "Hurry Up And Wait" Mode

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman Presents at Bank of America Merrill Lynch 2014 Healt

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman Presents at Bank of America Merrill Lynch 2014 Health Care Conference (Transcript)

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Deutsche Bank 39th Annual Health Care Conference

Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Deutsche Bank 39th Annual Health Care Conference (Transcript)

Bullish Two Hundred Day Moving Average Cross - NBIX

Neurocrine Biosciences' CEO Discusses Q1 2014 Results - Earnings Call Transcript

Will These 3 Drugs Keep AbbVie's Future Bright After Humira?

While generic drugmakers will have a whale of a challenge creating a biosimilar of AbbVie's star drug Humira, this big pharma's thinking ahead with three up-and-coming drugs developing in its pipeline.

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences Is Now Oversold (NBIX)

See More Articles...